Ractigen Therapeutics Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $17M
Latest Deal Amount
  • Investors
  • 3

Ractigen Therapeutics General Information

Description

Developer of RNAa (RNA activation) based therapeutic platform. The company aims to bring therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its platform utilizes RNA activation technology, enabling clients to specifically target and up-regulate therapeutic genes inside cells of the body. The company's mission is to offer a practical solution to combat disease at the genetic and epigenetic level.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • Bldg.18, Rudong Life & Health Industry Park
  • No. 888 Zhujiang Rd, Rudong County
  • Nantong, Jiangsu 226400
  • China
+86 0513 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ractigen Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 11-Feb-2021 $17M 00.000 Completed Generating Revenue
1. Early Stage VC 25-Oct-2016 00.000 00.000 Completed Startup
To view Ractigen Therapeutics’s complete valuation and funding history, request access »

Ractigen Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Longcheng Li MD Chief Executive Officer, President & Co-Founder
To view Ractigen Therapeutics’s complete executive team members history, request access »

Ractigen Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CCB International PE/Buyout Minority 000 0000 000000 0
Hillhouse Capital Group PE/Buyout Minority 000 0000 000000 0
Longmen Capital Venture Capital Minority 000 0000 000000 0
To view Ractigen Therapeutics’s complete investors history, request access »